Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1GlobeNewsWire • 06/03/23
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/15/23
Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated MilestonesGlobeNewsWire • 05/15/23
Sutro Biopharma, Inc. (STRO) Soars 11.3%: Is Further Upside Left in the Stock?Zacks Investment Research • 05/04/23
Sutro Biopharma, Inc. (STRO) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 05/01/23
Sutro Biopharma Announces the Departure of President of Research & Chief Scientific OfficerGlobeNewsWire • 04/27/23
Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023GlobeNewsWire • 04/18/23
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 03/31/23
Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated MilestonesGlobeNewsWire • 03/30/23
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 03/17/23
Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian CancerGlobeNewsWire • 01/09/23
Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/23
Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian CancerGlobeNewsWire • 12/21/22
Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free ExtractGlobeNewsWire • 12/20/22
Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022GlobeNewsWire • 12/10/22
How Much Upside is Left in Sutro Biopharma, Inc. (STRO)? Wall Street Analysts Think 214%Zacks Investment Research • 11/11/22
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/08/22
Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated MilestonesGlobeNewsWire • 11/08/22
Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and ExpositionGlobeNewsWire • 11/03/22